“Embedded in Lupin is a formula for growth which fuels creativity, performance and innovation”
It was Dr. Desh Bandhu Gupta’s vision and passion which helped him grow a small dream into a large company with a global footprint.
The most advanced pharmaceutical product development
Developing new chemical entities for focused therapy areas
Producing quality medicines in areas of
Producing high quality affordable
and accessible biologics
Mrs. Manju D Gupta
Chairperson (Non Executive)
Dr. Kamal K Sharma
Vice Chairman (Non Executive)
Ms. Vinita Gupta
Chief Executive Officer
Mr. Nilesh Deshbandhu Gupta
Mr. Ramesh Swaminathan
Executive Director, Global Chief Financial Officer & Head Corporate Affairs
Mr. R A Shah
Mr. Richard Zahn
Dr. K U Mada
Mr. Dileep C Choksi
Mr. Jean-Luc Belingard
Ms. Christine Mundkur
Committees of the Board of Directors.
Mr. Alok Sonig
CEO, US Generics
Head Global R&D & Biosimilars
Mr. Anil Kaushal
Dr. Cyrus Karkaria
Mr. Debabrata Chakravorty
Global Sourcing & Contract Manufacturing
Dr. Fabrice Egros
President – Growth Markets
Mr. Alan Butcher
Chief Corporate Development Officer
Mr. Naresh Gupta
President, API Plus & Global TB
Mr. Jon Stelzmiller
President, Specialty, USA
Mr. Rajeev Sibal
India Region Formulations (IRF)
Dr. Rajender Kamboj
President, Novel Drug Discovery and Development
Mr. Rajendra Chunodkar
President - Manufacturing Operations
Dr. Sofia Mumtaz
Pipeline Management and Legal
Mr. Sunil Makharia
Mr. Thierry Volle
Europe, Middle-East & Africa
Mr. Yashwant Mahadik
President, Global Human Resources
Mr. Johnny Mikell
President, Global Head of Quality
Mr. R V Satam
Mr. Arvind Bothra
Head - Investor Relations and M&A / Corporate Communications
Ms. Mundkur most recently served as Chief Executive Officer and Non-voting Chairman of the Board of Directors for Impopharma Inc, a developer of complex formulations focused on inhalation pharmaceutical products. While at Impopharma, she led the transition of the company from a successful clinical research organization into a generic pharmaceutical inhalation development company. She also held leadership positions as President and Chief Executive Officer for North America for Sandoz, Inc. Earlier, she served as Chief Executive Officer of Barr Laboratories, Inc. Ms. Mundkur started her career at Barr as quality and regulatory counsel. In addition, she served as a strategic advisor to clients on generics, 505(b)2, biosimilars and NDA business strategies. She currently serves on the Board of Directors for MannKind Corporation in the U.S.
Ms. Mundkur holds a J.D. from the St. Louis University School of Law and also received a B.S. degree in chemistry from St. Louis University.
File size : 1.8 MB
Mr Belingard, a French national, graduated from Ecole des Hautes Etudes Commerciales (HEC), France and completed Master of Business Administration from Cornell University, USA. Mr Belingard started his career with Merck, Sharp and Dohme. He moved to F. Hoffman-La Roche, Basel, Switzerland. He was Member of the Executive Committee, F. Hoffman-La Roche Ltd. and Chief Executive Officer, Roche Diagnostics, Basel, Switzerland. He was Chief Executive Officer, bioMerieux-Pierre Fabre, France. He was Chairman and Chief Executive Officer, Ipsen Group, France. In 2011, he joined bioMerieux S.A. as Chief Executive Officer and became its Chairman in April 2014. Mr Belingard is a Member of the Board of Directors of Laboratory Corporation of America, (U.S.A.), Stallergenes (France/U.S.A.), Transgene (France) and Laboratoire Pierre Fabre, (France). He is also a Member of the Bill and Melinda Gates Foundation. Mr Belingard is also Foreign Trade Advisor to the French Government. Mr Belingard has been conferred upon the prestigious National Awards, Chevalier de I’Ordre National du Merite and Chevalier de la Legion d’Honneur awards.
File size : 2.2 MB
Mr Dileep C Choksi, a leading Chartered Accountant by profession, has over 35 years of experience having qualified as a lawyer and a Cost Accountant. His areas of specialisation include tax planning and structuring for domestic and international clients, including expatriates, finalising collaborations and joint ventures, executive advisory and decision support, corporate restructuring with a focus on startup, turnaround and change management strategies and analysing tax impact of various instruments. He advises some of India’s largest business houses on various strategic matters and multinational clients on cross border structuring. Mr Choksi is on the Board and Committees of leading corporates. He was on the Advisory Board of foreign banks as well as Ex-Chairman of Banque Nationale De Paris, Bombay. He was the former Vice Chairman of Deloitte in India before setting up of C3 Advisors. The activities at C3 aim to provide complete answers for all business needs.
A Ph.D.in Economics from University of Bombay, with a Certificate in Financial Management from JBIMS, Dr K U Mada is an eminent economist and development banker. He has served in key positions with IDBI as its Executive Director for over three years. He was Chairman/Member of a number of committees constituted by IDBI and other financial institutions and the Government of India.
With more than 30 years of experience in the Biotechnology and Pharmaceutical Industries globally, Mr Richard Zahn is a well recognized thought leader and strategist in healthcare research and development, professional and consumer marketing, corporate strategy, sales force management, managed care, State and Federal relations, and human resources. Prior to this, Mr Zahn was the President of Schering Laboratories, Director, Schering Corporation and Corporate Vice President of Schering-Plough Corporation. As President of Schering, he directed the Corporation’s primary business unit through the most dynamic growth period in its history, transforming it from a US $1.5 billion organization to a US $ 6 billion major company. Under his stewardship, Schering Laboratories created and developed important prescription therapeutic markets. His leadership transformed Schering-Plough Healthcare Products (OTC company for Schering-Plough) into a major force. Mr Zahn spent 20 years rising through the ranks with increasing responsibility at Johnson & Johnson before being recruited to the Senior Management levels at Schering-Plough.
Mr R A Shah is an eminent Solicitor specialising in a broad spectrum of Corporate Laws. He is a senior partner of Crawford Bayley & Company, a leading firm of Solicitors and Advocates in Mumbai. He is on the boards of several reputed companies. Mr Shah is a member of the Managing Committee of Bombay Chamber of Commerce and Indo German Chamber of Commerce. He is President of Society of Indian Law Firms (Western Region).
Dr. Kamal K. Sharma is the Vice Chairman of the Board of Lupin Limited, in a Non-Executive capacity. In a career spanning more than four decades, Dr. Sharma has held a range of senior management positions managing projects, operations, corporate development and general management in the pharmaceuticals and chemicals industries. He was the Managing Director of Lupin Chemicals Limited which was rechristened Lupin Limited upon amalgamation with Lupin Laboratories Limited. Thereafter, he joined RPG Life Sciences, as President and Chief Executive Officer. In 2003 he rejoined Lupin Limited as Managing Director, following which he was appointed as Vice Chairman in 2013.
Dr. Sharma is a chemical engineer from Indian Institute of Technology (IIT), Kanpur, with a post-graduate diploma in industrial management from Jamnalal Bajaj Institute of Management Studies, Mumbai, and a Ph.D. in economics from IIT, Mumbai. He has also completed an advanced management programme from Harvard Business School, Boston.
Mrs. Manju D. Gupta is one of the promoters of the Company. She has intimate knowledge of the Company right since inception. Mrs. Gupta has been a Member of the Board for over four decades and has been an important pillar of strength for the Company. She has wide business experience and expertise and has been on various Committees of the Board and also involved in the CSR activities of the Company. Mrs. Gupta has made significant contribution in building the Company as one of the top corporates in India.
Mrs. Manju D. Gupta was Executive Director of the Company till August 10, 2017. The Board of Directors elevated her as Non-Executive Chairperson of the Company effective August 11, 2017.
Vinita Gupta is the CEO of Lupin Limited (Lupin) and Chairperson of Lupin Inc., (LI) and its US subsidiary, Lupin Pharmaceutical Inc. (LPI).
Vinita is a graduate in pharmacy from the University of Mumbai and earned an MBA degree at the Kellogg School of Management at Northwestern University. Vinita has been instrumental in formulating and executing a strategy that has helped the company emerge as a global pharmaceutical powerhouse; amongst the most exciting growth stories in the pharmaceutical industry. Through a combination of organic growth and strategic acquisitions, she has led the company’s global expansion plans. In particular, she founded, led and established Lupin’s largest region, the United States.
Vinita has been regularly named by Forbes Asia in its Top 50 Power Business women listings for Asia Pacific. Vinita was also recognized by Business Today Hall of Fame – Most Powerful Women in Business in 2016 and was recently named Outstanding Business Woman Leader of the Year by CNBC India Business Leader Awards. She was the winner of the inaugural EY, U.S. 2012 Family Business Award of Excellence and EY Entrepreneur Of the Year® 2012 award winner for Health Services and Technology in Maryland. She is regarded as amongst the most influential Indian Business Women globally.
Vinita along with her brother Nilesh (Managing Director, Lupin Limited) were named Ernst & Young (EY) Entrepreneur of The Year 2015 and won the Forbes India Leadership Awards 2016, Entrepreneur of the Year.
In 2017 Vinita was appointed to the board of directors for Intrexon Corporation. She is also a member of the Global Advisory Board at the Kellogg School of Management at Northwestern University.
Mr. Nilesh Gupta is the MD of Lupin Limited and a member of the Board of Directors. Having joined Lupin in 1996, Mr. Gupta led Lupin’s research, supply chain, manufacturing, quality and regulatory operations, and took charge as the company’s Managing Director in 2013. He has not only been responsible for transforming Lupin’s research program and expanding the company’s manufacturing operations but has also been instrumental in formulating and executing the core strategy that has helped Lupin emerge as a global specialty pharmaceutical major.
Mr. Gupta, along with his sister Vinita Gupta, won the Entrepreneur of the Year award at Forbes India Leadership Awards in 2016 as well as Ernst & Young ‘Entrepreneur of the Year Award’ in India in 2015, also with his sister Vinita Gupta.
Mr. Gupta is a Chemical Engineer from the University Department of Chemical Technology (UDCT) (now ICT), Mumbai, and a graduate with honours from the Wharton School, University of Pennsylvania, USA, where he specialized in healthcare, strategic management and finance.